Cargando…

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies

Cemiplimab, a human monoclonal antibody targeting programmed cell death-1 (PD-1) receptor, demonstrated antitumor activity in patients with advanced malignancies and a safety profile comparable to other anti–PD-1 therapies. This population pharmacokinetics (PopPK) analysis of cemiplimab included 11,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Feng, Paccaly, Anne J., Rippley, Ronda K., Davis, John D., DiCioccio, A. Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225544/ https://www.ncbi.nlm.nih.gov/pubmed/33728546 http://dx.doi.org/10.1007/s10928-021-09739-y

Ejemplares similares

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis
por: Paccaly, Anne J., et al.
Publicado: (2021)

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
por: Kovalenko, Pavel, et al.
Publicado: (2020)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2020)

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
por: Nguyen, Jenny‐Hoa, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

A drug‐disease model for predicting survival in an Ebola outbreak
por: Toroghi, Masood Khaksar, et al.
Publicado: (2022)

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
por: Kitano, Shigehisa, et al.
Publicado: (2020)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2021)

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
por: Zargham, Hanieh, et al.
Publicado: (2022)

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I
por: Martinez, Jean-Marie, et al.
Publicado: (2018)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Cemiplimab-Induced Alopecia Areata
por: Piraccini, Bianca Maria, et al.
Publicado: (2023)

Combined cemiplimab and radiotherapy for advanced basal cell carcinoma: A case report
por: Sarfaraz, Sidra, et al.
Publicado: (2023)

Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again
por: Davis, Christina M., et al.
Publicado: (2022)

Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal Volunteers
por: Kovalenko, P, et al.
Publicado: (2016)

Intravascular squamous cell carcinoma treated with cemiplimab
por: Rose, Alexander N., et al.
Publicado: (2021)

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
por: Van Meerhaeghe, T., et al.
Publicado: (2022)

Cemiplimab-Associated Sinusoidal Obstruction Syndrome
por: Sarsour, Nadeen Y., et al.
Publicado: (2023)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2021)

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
por: Denis, Chloé, et al.
Publicado: (2021)

Self‐resolving bullous pemphigoid induced by cemiplimab
por: Molle, Mattia Fabio, et al.
Publicado: (2022)

Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives
por: Mager, Layna, et al.
Publicado: (2023)

Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp
por: Paoluzzi, Luca, et al.
Publicado: (2021)

Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma
por: Virgen, Cesar A., et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020)

Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Lai, Fei Ya, et al.
Publicado: (2023)

Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis
por: Ma, Lei, et al.
Publicado: (2020)

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
por: Argenziano, Giuseppe, et al.
Publicado: (2022)

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
por: Paul, Eleanor, et al.
Publicado: (2021)

Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma
por: Marukian, Nareh Valerie, et al.
Publicado: (2020)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
por: Goodman, D.T.
Publicado: (2022)

Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?
por: Boziou, Maria, et al.
Publicado: (2023)

Novel genetic variants in miR-191 gene and familial ovarian cancer
por: Shen, Jie, et al.
Publicado: (2010)

Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios
por: Akhtar, Komal, et al.
Publicado: (2022)

Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
por: Rouvinov, Keren, et al.
Publicado: (2023)

Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
por: Ji, Tao, et al.
Publicado: (2022)

Effective Management of Nasal Vestibule Squamous Cell Carcinoma with Cemiplimab: A Case Report
por: Costabile, Ferdinando, et al.
Publicado: (2023)

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
por: Gogishvili, Miranda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q7e7rv0l4je1vatmc34u49255u